, the study of the influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs.
Addiction Labs of America, the American Addiction Centers' (NYSE: AAC) laboratory division, is in the early stages of developing a pharmacogenetics
test for cannabis and other cannabis products, such as cannabidiol, it was reported yesterday.
Doctors such as Bruce say they have seen promising patient results, but others say there is not enough solid evidence to show that pharmacogenetics
can work for the complexities of mental health treatment.
The Clinical Pharmacogenetics
Implementation Consortium (CPIC) has published guidelines describing the allele definitions, allele activity, and phenotypic interpretation.
His research at Columbia focuses on many aspects of human genetic variation including human genetic diversity, the genetics of disease, and pharmacogenetics
A current listing of all drugs with pharmacogenetics
labeling can be found in the FDA Table of Pharmacogenomics Biomarkers in Drug Labels.
de Mello et al., "Pharmacogenetics
of risperidone and cardiovascular risk in children and adolescents," International Journal of Endocrinology, vol.
works by leveraging information about an individual patient's genetic profile in order to select the best medications and dosages, which also helps to mitigate ineffective or possibly adverse drug reactions.
The World Innovation Summit for Health (WISH) has hosted a webinar discussing methods to improve the quality of healthcare by using pharmacogenetics
, a strategy aimed at ensuring the correct use of drugs for each patient to avoid negative side-effects.
Rennova Health previously announced in March 2016 that it had partnered with Genomas on the launch of a series of pharmacogenetics
tests that are performed via an FDA-approved in vitro diagnostic genotyping kit developed by Genomas and performed in Genomas' laboratory.
Others address the treatment of addiction, predicting drug obehavioro in humans, prefrontal cortex targets for cognition, melatonin receptors, neurotransmitter transporters, G protein-coupled receptor heteromers, genome integrity in aging, oxysterols, receptor activity-modifying proteins, pluripotent stem cells and neurodegenerative diseases, the role of spinal dynorphin in chronic pain, the design of next-generation G protein-coupled receptor drugs, nonclinical tools to assess the risk of drug hypersensitivity reactions, sleep pharmacogenetics
and personalized sleep-wake therapy, nuclear receptors as therapeutic targets in liver disease, and epidermal growth factor receptor transactivation in the cardiovascular system.
Furthermore, the study "clearly demonstrated a relationship between oxycodone steady-state drug concentrations and pain relief," and called for more large-scale studies in order to confirm these findings and focus pain management therapy on pharmacogenetics
for prescribing opioids.